

%201.webp)


%201.webp)




LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。



%201.webp)


%201.webp)




序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

Pharmaceutical products in Canada are regulated by Health Canada under the Food and Drugs Act and the Food and Drug Regulations. Health Canada oversees the authorization, labeling, manufacturing, importation, and distribution of medicines to ensure product safety, quality, and efficacy.
Canada does not currently operate a national pharmaceutical serialization or track and trace system similar to those implemented in the United States, European Union, or several Middle East and CIS countries. Instead, regulatory oversight focuses on product authorization, good manufacturing practices, labeling compliance, and pharmacovigilance.
Canada has implemented drug identification and verification mechanisms, including the Drug Identification Number (DIN) and national drug product databases that allow regulators and healthcare professionals to verify approved medicines. Supply chain traceability is generally managed through industry systems and wholesale distribution records, rather than through a centralized regulatory serialization platform.
All medicines sold in Canada must comply with labeling requirements defined under the Food and Drug Regulations and Health Canada guidance.
Key labeling elements include:
Labels must be provided in both English and French, Canada's official languages.
Barcodes may be included on pharmaceutical packaging for supply chain management and pharmacy scanning purposes, but unit level serialization is not currently mandated by Health Canada.
1953 - Canada enacted the Food and Drugs Act, establishing the national framework for regulating pharmaceuticals and health products.
1995 onward - Health Canada introduced modern regulatory processes for drug approval and safety monitoring.
2001 - Canada launched the Drug Product Database (DPD) to provide public access to approved medicines. Canada continues to regulate pharmaceuticals through product authorization, quality oversight, and pharmacovigilance rather than serialization or national traceability.
Marketing authorization holders and distributors are responsible for ensuring that medicines remain compliant throughout the product lifecycle.
Canada does not operate a national pharmaceutical traceability reporting hub.
Regulatory oversight is managed through several Health Canada systems and databases:
Drug Identification Number (DIN) System
Every authorized medicine receives a unique DIN that identifies the product formulation, manufacturer, and therapeutic classification.
Drug Product Database (DPD)
Public database that provides information about authorized drug products in Canada.
Drug Establishment Licensing (DEL)
Ensures manufacturers, importers, distributors, and wholesalers comply with Good Manufacturing Practices.
Canada Vigilance Program
National system used for adverse drug reaction reporting and safety monitoring.
These systems support regulatory oversight but do not track serialized product movement within the supply chain.
Canada does not require aggregation or serialization for pharmaceutical products.
However, many pharmaceutical manufacturers operating in Canada voluntarily implement serialization and aggregation to support global export requirements, particularly for markets such as the United States, European Union, and GCC countries that mandate serialization.
These voluntary systems typically follow GS1 standards to support supply chain automation and product verification.
We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.